medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2017, Número 6

<< Anterior Siguiente >>

Acta Pediatr Mex 2017; 38 (6)


Cambiando los paradigmas de la infección por M. pneumoniae en pediatría

Merida-Vieyra J, Aquino-Andrade A, Ribas-Aparicio RM, De Colsa- Ranero A

Idioma: Español
Referencias bibliográficas: 79
Paginas: 412-426
Archivo PDF: 1495.99 Kb.


RESUMEN

La neumonía atípica es un término que originalmente se utilizó en pacientes adultos que presentaban neumonías de curso atípico, generalmente leves y de evolución benigna, que eran causadas por agentes como: Mycoplasma pneumoniae, Chlamydophila pneumoniae y Legionella pneumophila. En población pediátrica la presentación, tanto clínica como epidemiológica, de las neumonías por M. pneumoniae merece una especial atención ya que no siempre son cursos benignos y pueden existir numerosos cuadros extrapulmonares asociados; el proceso diagnóstico es complejo y poco diferencial de otros agentes etiológicos. Recientemente ha llamado la atención la emergencia de la resistencia a macrólidos en algunos países del mundo, por lo que existen controversias respecto al tratamiento. Estudios numerosos realizados a nivel mundial, particularmente derivados de países asiáticos, han generado nueva información en relación al comportamiento biológico, clínico, epidemiológico, radiológico y respuesta terapéutica de M. pneumoniae en pacientes pediátricos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Waites KB, Xiao L, Paralanov V, Viscardi RM, Glass JI. Mycoplasma and Ureaplasma. Mol Typing Bact Infect. Primera. New York: Springer Science+Business Media; 2013. p. 229–281.

  2. Waites KB, Simecka JW, Talkington DF, Prescott T. Pathogenesis of Mycoplasma pneumoniae infections: adaptive immunity, innate immunity, cell biology, and virulence factors. Community Acquir-Pneumonia. Switzerland: Birkhäuser Verlag Basel; 2007. p. 183–199.

  3. Matas Andreu L, Molinos Abós S, Fernández Rivas G, González Soler V, Ausina Ruiz V. Serologic diagnosis of Mycoplasma pneumoniae infections. Enferm Infecc Microbiol Clin. 2006;24(1):19–23.

  4. He X, Wang X, Zhang R, Yuan Z, Tan J, Peng B, et al. Investigation of Mycoplasma pneumoniae infection in pediatric population from 12,025 cases with respiratory infection. Diagn Microbiol Infect Dis. 2013;75(1):22–27.

  5. Diaz MH, Benitez AJ, Cross KE, Hicks LA, Kutty P, Bramley AM, et al. Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infect Dis. 2015;2(3):ofv106.

  6. Chiang WC, Teoh OH, Chong CY, Goh A, Tang JPL, Chay OM. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirol Carlton Vic. 2007;12(2):254–261.

  7. Ma Y-J, Wang S-M, Cho Y-H, Shen C-F, Liu C-C, Chi H, et al. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: A nationwide surveillance. J Microbiol Immunol Infect. 2015;48(6):632–638.

  8. Vervloet LA, Vervloet VEC, Tironi Junior M, Ribeiro JD. Mycoplasma pneumoniae-related community-acquired pneumonia and parapneumonic pleural effusion in children and adolescents. J Bras Pneumol. 2012;38(2):226–236.

  9. Waites KB. ¿What´s new in diagnostic testing and treatment approaches for Mycoplasma pneumoniae infections in children? Hot Top Infect Immun Child V. New York: Springer; 2011. p. 45–57.

  10. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017;30(3):747–809.

  11. Almasri M, Papa A, Souliou E, Haidopoulou K, Eboriadou M. Respiratory syncytial virus infection in hospitalized children older than 2 years with community-acquired pneumonia. Hippokratia. 2013;17(2):146–149.

  12. Cantais A, Mory O, Pillet S, Verhoeven PO, Bonneau J, Patural H, et al. Epidemiology and microbiological investigations of community-acquired pneumonia in children admitted at the emergency department of a university hospital. J Clin Virol. 2014;60(4):402–407.

  13. Carcey J, Garcia P, Padilla O, Castro-Rodriguez JA. Increased prevalence of Mycoplasma pneumoniae serological positivity in Chilean young children. Allergol Immunopathol (Madr). 2016;44(5):467–471.

  14. De Schutter I, De Wachter E, Crokaert F, Verhaegen J, Soetens O, Piérard D, et al. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: identification of nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis. 2011;52(12):1437–1444.

  15. Del Valle-Mendoza J, Orellana-Peralta F, Marcelo-Rodríguez A, Verne E, Esquivel-Vizcarra M, Silva-Caso W, et al. High Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in Children with Acute Respiratory Infections from Lima, Peru. PloS One. 2017;12(1):e0170787.

  16. Feikin DR, Njenga MK, Bigogo G, Aura B, Aol G, Audi A, et al. Etiology and Incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007-2010. PloS One. 2012;7(8):e43656.

  17. Ferrero FC, Ossorio MF, Eriksson PV, Duran AP. Mycoplasma pneumoniae en niños con neumonía. Arch Argent Pediatr. 2000;98(1):12–17.

  18. Grassi T, Mancini F, Ciervo A, Vescio MF, Ghazal A, Ashour H, et al. Chlamydophila pneumoniae, Mycoplasma pneumoniae, and influenza in children with respiratory infections in Alexandria, Egypt. J Infect Dev Ctries. 2014;8(3):379–383.

  19. Herrera M, Aguilar YA, Rueda ZV, Muskus C, Vélez LA. Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria. J Negat Results Biomed. 2016;15:3. doi.org/10.1186/s12952-016-0047-y

  20. Huong PLT, Hien PT, Lan NTP, Binh TQ, Tuan DM, Anh DD. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1-15 years. BMC Public Health. 2014;14:1304. doi: 10.1186/ s41479-017-0031-4

  21. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T, Oba K, et al. Regional Differences in Prevalence of Macrolide Resistance among Pediatric Mycoplasma pneumoniae Infections in Hokkaido, Japan. Jpn J Infect Dis. 2016;69(3):186–190.

  22. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845.

  23. Jonnalagadda S, Rodríguez O, Estrella B, Sabin LL, Sempértegui F, Hamer DH. Etiology of severe pneumonia in Ecuadorian children. PloS One. 2017;12(2):e0171687.

  24. Kicinski P, Wisniewska-Ligier M, Wozniakowska-Gesicka T. Pneumonia caused by Mycoplasma pneumoniae and Chlamydophila pneumoniae in children - comparative analysis of clinical picture. Adv Med Sci. 2011;56(1):56–63.

  25. Kogoj R, Mrvic T, Praprotnik M, Kese D. Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014. Euro Surveill. 2015;20(37). doi: 10.2807/1560-7917.ES.2015.20.37.30018.

  26. Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirol Carlton Vic. 2004;9(1):109–114.

  27. Kurz H, Göpfrich H, Huber K, Krugluger W, Asbott F, Wabnegger L, et al. Spectrum of pathogens of in-patient children and youths with community acquired pneumonia: a 3 year survey of a community hospital in Vienna, Austria. Wien Klin Wochenschr. 2013;125(21–22):674–679.

  28. Lassmann B, Poetschke M, Ninteretse B, Issifou S, Winkler S, Kremsner PG, et al. Community-acquired pneumonia in children in Lambarene, Gabon. Am J Trop Med Hyg. 2008;79(1):109–114.

  29. Liao J-Y, Zhang T. Distribution characteristics of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in hospitalized children with acute respiratory tract infection: an analysis of 13 198 cases. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(7):607–613.

  30. Lochindarat S, Suwanjutha S, Prapphal N, Chantarojanasiri T, Bunnag T, Deerojanawong J, et al. Mycoplasma pneumoniae and Chlamydophila pneumoniae in children with community-acquired pneumonia in Thailand. Int J Tuberc Lung Dis. 2007;11(7):814–819.

  31. Lova R, Naim B, Rakotomahefa M, Andrianirina AZ, Robinson AL, Raobidjaona H, et al. Prevalence of Mycoplasma pneumoniae infection in Malagasy children. Pediatr Infect Dis J. 2017;36(5):467-471.

  32. Mathew JL, Singhi S, Ray P, Hagel E, Saghafian-Hedengren S, Bansal A, et al. Etiology of community acquired pneumonia among children in India: prospective, cohort study. J Glob Health. 2015;5(2):050418. doi: 10.7189/jogh.05.020418.

  33. Matute AJ, Brouwer WP, Hak E, Delgado E, Alonso E, Hoepelman IM. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua. Int J Antimicrob Agents. 2006;28(5):423–427.

  34. Medjo B, Atanaskovic-Markovic M, Radic S, Nikolic D, Lukac M, Djukic S. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital J Pediatr. 2014;40:104. doi: 10.1186/s13052-014-0104-4

  35. Meyer Sauteur PM, Bleisch B, Voit A, Maurer FP, Relly C, Berger C, et al. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Med Wkly. 2014;144:w14041.

  36. Sáez-Llorens X, Castaño E, Wubbel L, Castrejón MM, de Morales I, Vallarino D, et al. Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia. Rev Med Panama. 1998;23(2):27–33.

  37. Kenri T, Okazaki N, Yamazaki T, Narita M, Izumikawa K, Matsuoka M, et al. Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains. J Med Microbiol. 2008;57(Pt 4):469–475.

  38. Edelstein I, Rachina S, Touati A, Kozlov R, Henin N, Bébéar C, et al. Mycoplasma pneumoniae Monoclonal P1 Type 2c Outbreak, Russia, 2013. Emerg Infect Dis. 2016;22(2):348–350.

  39. Meyer Sauteur PM, Unger WWJ, Nadal D, Berger C, Vink C, van Rossum AMC. Infection with and Carriage of Mycoplasma pneumoniae in Children. Front Microbiol. 2016;7:329. doi.org/10.3389/fmicb.2016.00329

  40. Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, et al. Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia. Open Forum Infect Dis. 2016;3(2):ofw071.

  41. Spuesens EBM, Fraaij PLA, Visser EG, Hoogenboezem T, Hop WCJ, van Adrichem LNA, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10(5):e1001444.

  42. Chaudhry R, Ghosh A, Chandolia A. Pathogenesis of Mycoplasma pneumoniae: An update. Indian J Med Microbiol. 2016;34(1):7–16.

  43. Jiang W, Qian L, Liang H, Tian M, Liu F, Zhao D. Relationships between the varied ciliated respiratory epithelium abnormalities and severity of Mycoplasma pneumoniae pneumonia. Scand J Infect Dis. 2014;46(7):486–492.

  44. Shimizu T. Inflammation-inducing Factors of Mycoplasma pneumoniae. Front Microbiol. 2016;7:414. doi: 10.3389/ fmicb.2016.00414

  45. Saraya T. The History of Mycoplasma pneumoniae Pneumonia. Front Microbiol. 2016;7:364. doi: 10.3389/ fmicb.2016.00364

  46. Parrott GL, Kinjo T, Fujita J. A Compendium for Mycoplasma pneumoniae. Front Microbiol. 2016;7:513. doi: 10.3389/ fmicb.2016.00513

  47. Miyashita N, Narita M, Tanaka T, Akaike H, Teranishi H, Oishi T, et al. Histological findings in severe Mycoplasma pneumoniae pneumonia. J Med Microbiol. 2017;66(5):690–692.

  48. Dumke R, Jacobs E. Antibody Response to Mycoplasma pneumoniae: Protection of Host and Influence on Outbreaks? Front Microbiol. 2016;7:39. doi: 10.3389/ fmicb.2016.00039

  49. Simecka J. What we have Learned from Animal Models of Mycoplasma pneumoniae Disease: Virulence Mechanisms and Host Responses. Curr Pediatr Rev. 2013;9(4):314–323.

  50. Saraya T, Kurai D, Nakagaki K, Sasaki Y, Niwa S, Tsukagoshi H, et al. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications. Front Microbiol. 2014;5:410.

  51. Wang M, Wang Y, Yan Y, Zhu C, Huang L, Shao X, et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014;29:18–23.

  52. Waites KB, Atkinson TP. The role of Mycoplasma in upper respiratory infections. Curr Infect Dis Rep. 2009;11(3):198– 206.

  53. Narita M. Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis. Front Microbiol. 2016;7:23.

  54. Esposito S, Cavagna R, Bosis S, Droghetti R, Faelli N, Principi N. Emerging role of Mycoplasma pneumoniae in children with acute pharyngitis. Eur J Clin Microbiol Infect Dis. 2002;21(8):607–610.

  55. Kishaba T. Community-Acquired Pneumonia Caused by Mycoplasma pneumoniae: How Physical and Radiological Examination Contribute to Successful Diagnosis. Front Med. 2016;3:28.

  56. Wang K, Gill P, Perera R, Thomson A, Mant D, Harnden A. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev. 2012;10:CD009175.

  57. Yeh J-J, Wang Y-C, Hsu W-H, Kao C-H. Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study. J Allergy Clin Immunol. 2016;137(4):1017-1023.e1–6.

  58. Izumikawa K. Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Front Microbiol. 2016;7:800.

  59. Romero Reyes LE. Neumonía por Mycoplasma pneumoniae y Chlamydophila pneumoniae [Subpespecialidad en Infectología Pediátrica]. [Ciudad de México]: Universidad Nacional Autónoma de México; 2016.

  60. Chiu C-Y, Chen C-J, Wong K-S, Tsai M-H, Chiu C-H, Huang Y-C. Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. J Microbiol Immunol Infect. 2015;48(1):51–56.

  61. Gong L, Zhang C-L, Zhen Q. Analysis of clinical value of CT in the diagnosis of pediatric pneumonia and mycoplasma pneumonia. Exp Ther Med. 2016;11(4):1271–1274.

  62. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate Dehydrogenase as a Biomarker for Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. Respir Care. 2015;60(10):1469–1475.

  63. Vervloet LA, Marguet C, Camargos PAM. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Braz J Infect Dis. 2007;11(5):507–514.

  64. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956–973.

  65. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis. 2010;29(9):1055–1069.

  66. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635–648.

  67. Daxboeck F, Stadler M, Assadian O, Marko E, Hirschl AM, Koller W. Characterization of clinically isolated Ralstonia mannitolilytica strains using random amplification of polymorphic DNA (RAPD) typing and antimicrobial sensitivity, and comparison of the classification efficacy of phenotypic and genotypic assays. J Med Microbiol. 2005;54(Pt 1):55–61.

  68. Diaz MH, Winchell JM. The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae. Front Microbiol. 2016;7:232.

  69. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016;7:974.

  70. Spuesens EBM, Meyer Sauteur PM, Vink C, van Rossum AMC. Mycoplasma pneumoniae infections--does treatment help? J Infect. 2014;69 (1):S42-46.

  71. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–1090.

  72. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1:CD004875.

  73. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380–383.

  74. Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide- sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58(2):1034–1038.

  75. Citti C, Blanchard A. Mycoplasmas and their host: emerging and re-emerging minimal pathogens. Trends Microbiol. 2013;21(4):196–203.

  76. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001;45(8):617–620.

  77. Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PloS One. 2017;12(3):e0173635.

  78. Jensen KE, Senterfit LB, Chanock RM, Smith CB, Purcell RH. An inactivated Mycoplasma pneumoniae vaccine. JAMA. 1965;194(3):248–252.

  79. Hausner M, Schamberger A, Naumann W, Jacobs E, Dumke R. Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan. Microb Pathog. 2013;64:23–32.




2020     |     www.medigraphic.com